Biologicals

Molecular Methods

Vaccines and other biological medicines are derived from living materials. This poses particular problems with regard to assuring their efficacy and safety due to the inherent variability of starting materials, the production processes, and the complex nature of the products themselves. For vaccines and other biological medicines, the key to effective quality control (QC) is rigorous testing and validation applied to the starting materials, to different stages of the production process, and also to the final products.

With the advent of molecular biotechnology, there are increasing uses of molecular methods for the characterization and QC of vaccines whether they are currently used or newly developed. The World Health Organization Expert Committee on Biological Standardization (WHO ECBS) has put an increasing emphasis on products and assays arising from new biotechnology in internationally harmonized activities of quality assurance and safety of biologicals, and of vaccines in particular.


RELATED LINKS

UPCOMING EVENTS

WHO Collaborating Centers on Standardization on Regulatory Evaluation of Vaccines & Biotherapeutic Products: 1st meeting, Geneva, 24-26 April 2012

WHO Workshop on implementing WHO Guidelines on evaluating similar biotherapeutic products (SBPs), Xiamen, China, 28-30 May 2012

WHO Informal Consultation on the revision of the recommendations to assure the Quality, Safety and Efficacy of biological products prepared by recombinant DNA technology, Xiamen, China, 31 May-1 June 2012

CONTACTS

Quality, Safety and Standards (QSS)
Immunization, Vaccines and Biologicals (IVB)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971